(Reuters) – Novo Nordisk said on Monday the U.S. Food and Drug Administration has approved a higher dosage of 2 mg of Ozempic for the treatment of adults with type 2 diabetes.
Ozempic is now approved in the United States in doses of 0.5 mg, 1 mg and 2 mg, the company said.
(Reporting by Leroy Leo in Bengaluru; Editing by Shailesh Kuber)
